4-chloro-N-[2,2-dichloro-1-[(Z)-[(cyanoamino)-[(2-methoxypyridin-3-yl)amino]methylidene]amino]propyl]benzamide

ID: ALA240177

Max Phase: Preclinical

Molecular Formula: C18H17Cl3N6O2

Molecular Weight: 455.73

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ncccc1N/C(=N\C#N)NC(NC(=O)c1ccc(Cl)cc1)C(C)(Cl)Cl

Standard InChI:  InChI=1S/C18H17Cl3N6O2/c1-18(20,21)16(26-14(28)11-5-7-12(19)8-6-11)27-17(24-10-22)25-13-4-3-9-23-15(13)29-2/h3-9,16H,1-2H3,(H,26,28)(H2,24,25,27)

Standard InChI Key:  PCYQNSRPJFTODK-UHFFFAOYSA-N

Associated Targets(Human)

KCNJ11 Tclin Potassium channel, inwardly rectifying, subfamily J, member 11 (112 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P2RX7 Tchem P2X purinoceptor 7 (5534 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

P2rx7 P2X purinoceptor 7 (1132 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 455.73Molecular Weight (Monoisotopic): 454.0479AlogP: 3.53#Rotatable Bonds: 6
Polar Surface Area: 111.43Molecular Species: NEUTRALHBA: 5HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: CX LogP: 4.04CX LogD: 4.04
Aromatic Rings: 2Heavy Atoms: 29QED Weighted: 0.20Np Likeness Score: -1.50

References

1. Perez-Medrano A, Brune ME, Buckner SA, Coghlan MJ, Fey TA, Gopalakrishnan M, Gregg RJ, Kort ME, Scott VE, Sullivan JP, Whiteaker KL, Carroll WA..  (2007)  Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.,  50  (24): [PMID:17973362] [10.1021/jm7010194]
2. Perez-Medrano A, Donnelly-Roberts DL, Honore P, Hsieh GC, Namovic MT, Peddi S, Shuai Q, Wang Y, Faltynek CR, Jarvis MF, Carroll WA..  (2009)  Discovery and biological evaluation of novel cyanoguanidine P2X(7) antagonists with analgesic activity in a rat model of neuropathic pain.,  52  (10): [PMID:19397270] [10.1021/jm8015848]

Source